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ABSTRACT
ALARANTA, A., H. ALARANTA, M. HELIO¨ VAARA, P. ALHA, P. PALMU, and I. HELENIUS. Allergic Rhinitis and Pharma-
cological Management in Elite Athletes. Med. Sci. Sports Exerc., Vol. 37, No. 5, pp. 707–711, 2005. Introduction: Only a few studies
have examined the occurrence of atopy and clinically apparent allergic disease and their pharmacological management in elite athletes.
The aim of the study was to assess the frequency of allergic rhinitis and the use of antiallergic medication within the subgroups of elite
athletes as compared with a representative sample of young adults of the same age. Methods: A cross-sectional survey was carried out
in 2002. All the athletes (N  494) financially supported by the National Olympic Committee comprised the study group. Of them,
446 (90.3%) filled in a structured questionnaire concerning asthma and allergies, the use of medication, characteristics of sport
activities, and smoking habits. A representative sample of Finnish young adults (N 1504) served as controls. Results: The endurance
athletes reported physician-diagnosed allergic rhinitis more often (36.1%) than other athletes (23.4%) or control subjects (20.2%). The
use of antiallergic medication was reported by 33.3, 15.7, and 15.6% of those, respectively. Among both athletes and controls, females
reported the use of antiallergic medication more often than males. Only half of those athletes reporting allergic rhinitis had used
antiallergic medication during the past year. After adjusting for age and sex, OR (95% CI) for allergic rhinitis and the use of antiallergic
medication were 2.24 (1.48–3.39) and 2.79 (1.82–4.28), respectively, in endurance athletes as compared with the controls. Conclu-
sions: Endurance athletes have physician-diagnosed allergic rhinitis, and they use antiallergic medication more often than athletes in
other events or control subjects. Only half of those athletes reporting allergic rhinitis take antiallergic medication. More attention needs
to be paid to the optimal management of allergic rhinitis, especially in highly trained endurance athletes. Key Words: ANTIALLER-
GIC MEDICATION, ALLERGIC RHINOCONJUNCTIVITIS, ANTIHISTAMINES, INTRANASAL CORTICOSTEROIDS, EN-
DURANCE ATHLETE
Sport exercise may increase ventilation up to 200L·min1 for short periods of time in speed and powerathletes and for longer periods in endurance athletes
(8). When the ventilation level exceeds about 30 L·min1, a
shift occurs from nasal breathing to combined mouth and
nasal breathing (3). This shift results in a greater deposition
of airborne allergens and other inhaled particles into the
athlete’s lower airways; in addition, incompletely condi-
tioned air may reach the mucous membranes of the lower
airways (18). Athletes who participate in summer events are
intensively exposed to airborne allergens during their train-
ing and competitions, whereas winter sport athletes are
exposed to cold air (20). Swimmers are exposed to chlorine
compounds. In skiers (8,15,19), the association between
atopy, respiratory allergy, and asthma has not been demon-
strated to be as clear as in summer sport athletes (9,10).
Indeed, allergic rhinitis (AR) and atopy are more common in
endurance athletes competing in summer events as com-
pared with control subjects (9), whereas the occurrence of
atopy in skiers is similar as in control subjects (19).
Nasal mucosal swelling may lead to compromised drain-
age of the related anatomical systems, which may lead to
acute or chronic infection (13). Chronic AR is associated
with many complications. Nasal obstruction on a long-term
basis often leads to snoring, sleep disturbance, headaches,
and fatigue, all of which will impair a person’s quality of
life. Impaired sleep, together with irritability caused by this
condition, can have a significant impact on a person’s qual-
ity of life by leading to poor performance and chronic
Address for correspondence: Antti Alaranta, M.Sc. (Pharm), Tammelankatu
8 B 10, FIN-04430 Ja¨rvenpa¨a¨, Finland; E-mail: antti.alaranta@helsinki.fi.
Submitted for publication September 2004.
Accepted for publication December 2004.
0195-9131/05/3705-0707
MEDICINE & SCIENCE IN SPORTS & EXERCISE®
Copyright © 2005 by the American College of Sports Medicine
DOI: 10.1249/01.MSS.0000162689.69517.60
707
tiredness. When AR affects elite athletes, however, these
quality-of-life issues make it particularly troublesome, and it
may cause significant impairment in their athletic perfor-
mances. During exercise, minute ventilation increases,
which brings the nasal passages into contact with greater
volumes of air and therefore allergens, so symptoms are
commonly experienced during exercise. For example, a
short burst of sprinting requires combined mouth and nasal
breathing for optimal performance, so a change in the indi-
vidual’s pattern of breathing because of nasal obstruction
may affect performance. Untreated AR may also compro-
mise the treatment of asthma in elite athletes (4). Further-
more, several studies have shown that AR is underrecog-
nized and certainly undertreated in elite athletes (7,14). It
has been suggested that strong and repeated exposure to air-
borne allergens causes not only bronchial symptoms but also
AR in elite summer sport athletes (20).
The pharmacological management of AR has to comply
with antidoping regulations. The goal of the therapy is
optimum symptom control while minimizing the detrimen-
tal influences on performance from adverse effects. Re-
cently, caffeine, pseudoephedrine, and phenylpropanol-
amine were declassified by the WADA. This facilitates the
pharmacological care of AR in elite athletes and removes
the concern for the positive test results when these sub-
stances are used unintentionally for the management of AR.
The results of the IOC accredited laboratories show that
nearly one third of the positive results for stimulants were
for these three substances in 2002 (IOC statistics 2002, Over-
view on the results reported by the IOC accredited laboratories,
http://multimedia.olympic.org/pdf/en_report_632.pdf).
Whereas the impact of exercise-induced asthma and in-
creased bronchial responsiveness on athletes’ performance
has been studied extensively, only a few studies have ex-
amined the occurrence of atopy and clinically apparent
allergic disease and their pharmacological management in
elite athletes. The aim of the study was to assess the fre-
quency of AR, other allergic conditions, and the use of
antiallergic medication within the different groups of sport
activities in a large sample of Finnish top elite athletes.
These athletes were also compared with a representative
sample of young adults of the same age.
METHODS
Study design for athletes. A cross-sectional ques-
tionnaire survey was carried out in 2002. All athletes (N 
494) eligible for financial support of National Olympic
Committee comprised the source population for this study.
They were asked to complete the questionnaire at their
national team camps during the study period, and if they
were absent, the questionnaire was sent to them by mail. Of
the 494 athletes, 446 (90.3%) filled in a structured ques-
tionnaire after accepting written informed consent. The ath-
letes were divided into four groups according to their type of
sport. The four groups were speed and power sport athletes,
endurance athletes, athletes in motor skills demanding
events, and team sport athletes. The characteristics of the
four study groups are given in the Table 1. The inclusion
criteria and methods employed have been described in de-
tails previously in this journal (1).
Control subjects. The reference group consisted of all
persons aged 18–29 yr (N  1894) from the Finnish Na-
tional Health Survey Health 2000, coordinated by the Na-
tional Public Health Institute. A nationally representative
two-stage cluster sample was drawn, which consisted of
10,000 persons and 80 regions (municipalities or groups of
municipalities with joint primary care). The sample included
inhabitants of all the 15 largest cities and towns. The sub-
study of younger adults aged 18–29 consisted of a comput-
er-aided health interview carried out during the spring and
summer of 2001. The final size of the sample of those aged
18–29 was 1876, of which 1504 (80.2%) participated in the
health interview. The data was collected, stored, analyzed,
and reported anonymously according to the law of data
protection in Finland.
Questionnaire. Questions concerned asthma, exercise-
induced bronchial symptoms, the use of asthma and allergy
medication, the characteristics of sport activities, educa-
tional level, and smoking habits (1). The subjects were
asked whether they had a disturbing allergy that had been
diagnosed by a physician. When the subject responded
affirmatively to the question, the subject was further asked
whether the condition was AR, allergic conjunctivitis,
atopic eczema, or other. The subjects were also asked
whether they had any current medication for their condition.
If they had, they were asked to list all the preparations used
during the previous 12 months. The subjects were further
asked whether they used above mentioned medication reg-
ularly or as needed. In addition, they were asked if they had
taken these preparations during the last 7 d (yes/no).
In the results section, sympathomimetics include products
containing phenylpropanolamine or pseudoephedrine. Anti-
allergic nasal sprays without corticosteroids include prod-
ucts containing disodium cromoglycate or levocabastine.
Statistical methods. The odds ratios (OR) for AR and
atopic eczema and their 95% confidence intervals (95% CI)
for athlete subgroups compared with controls were analyzed
TABLE 1. Characteristics of the subgroups.
All Athletes
(N  446/494)
Speed and Power
Events (N  113)
Endurance Events
(N  108)
Motor
Skills–Demanding
Events (N  73)
Team Sport
Events (N  152)
Controls
(N  1504/1876)
Sex (men/women) 261/185 82/31 62/46 45/28 72/80 766/738
Mean (SD) age (yr) 23.0 (4.5) 23.8 (4.1) 23.6 (4.0) 23.6 (6.5) 21.6 (3.6) 23.4 (3.5)
Mean (SD) duration of active sport career (yr) 11.7 (4.3) 12.2 (3.7) 12.4 (4.6) 11.9 (5.0) 10.8 (4.1) —
Mean (SD) training amount (hwk1) 15.4 (6.1) 15.5 (4.6) 17.3 (5.9) 15.1 (7.4) 14.1 (6.3) —
Response rate (%) 90.3 89.0 90.8 82.0 95.6 80.2
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using a logistic regression model (SPSS 10.0 software).
Age, sex, and type of sport were included as independent
covariates in the analysis.
The sample-size requirement was calculated using a study
power of 80%, a Type I error  of 0.05, and an estimated
prevalence of 25 and 15% for AR in the athlete and control
group, respectively (9). A total of 249 study subjects in both
groups were required to identify a 10% difference in prev-
alence rates between these groups.
RESULTS
No statistical difference was found in the occurrence of a
disturbing allergy (32.1 vs 30.1%; Table 2), or in the age-
and sex-adjusted OR between athletes and controls (OR,
1.12; 95% CI, 0.89–1.41). A physician-diagnosed AR was
reported by 26.5% (118 of 446) of the athletes and by 20.2%
(303 of 1503) of the controls (Table 2). After adjusting for
age and sex, the OR (95% CI) for physician diagnosed AR
was significantly higher among endurance athletes as com-
pared with controls (OR, 2.24; 95% CI, 1.48–3.39; Table 4).
The athletes reported the use of antiallergic medication
significantly more often than the controls did (20.0 vs
15.6%; OR, 1.42; 95% CI, 1.08 –1.87). A total of 12.6%
(56 of 446) of the athletes and 6.3% (94 of 1503) of the
controls reported using antiallergic medication during the
last 7 d. Of the athletes 4.9% (34/446) and 2.3% (34/1
503) of the controls reported using antiallergic medica-
tion regularly. After adjusting for age, and sex, the OR for
the use of any antiallergic medication was significantly
higher among endurance athletes than for the controls
(OR, 2.79; 95% CI, 1.82– 4.28; Table 4). No significant
difference existed between winter and summer sport ath-
letes in AR or use of medication.
Allergic conjunctivitis was reported by 3.6% of the ath-
letes and 5.6% of the controls. The women, both the athletes
and controls, reported this condition more often than the
men (Table 2). In both groups, the women used antiallergic
eyedrops more often than men did (Table 3).
The most commonly used antiallergy drugs in all study
groups were oral antihistamines, followed by intranasal
corticosteroids. A significant difference was observed in the
frequency of oral antihistamine use between different sport
events, with the endurance athletes reporting treatment most
often. After adjusting for age, and sex, the OR (95% CI) for
the use of oral antihistamines was significantly higher
among endurance athletes than in the general population
(OR, 2.52; 95% CI, 1.54–4.12, Table 4). Among those with
a history of any allergy, no significant difference in the use
of antiallergic medication was found between various
groups of athletes and the general population.
A total of 55.1% (65 of 118) of those athletes and
53.5% (162 of 303) of the controls having physician-
diagnosed rhinitis reported using antiallergic medication.
Female athletes with physician diagnosed AR used anti-
allergic medication more often than male athletes (65.3%
(32 of 49) vs 47.8% (33 of 69)). Of the athletes reporting
AR, 34.7% (41 of 118) also had physician-diagnosed
asthma, whereas 6.4% (21 of 328) of those athletes who
did not report AR had asthma.
TABLE 3. Prevalence (%) of the use of antiallergic medication during the previous 12 months.
Oral
Antihistamines
Intranasal
Corticosteroids Sympathomimetcs
Antiallergic Nasal
Sprays without
Corticosteroids
Antiallergic
Eyedrops
Any
Antiallergic
Drug
All athletes 13.7 (61/446) 6.1 (27/446) 1.3 (6/446) 1.3 (6/446) 2.2 (10/446) 20.0 (89/446)
Women 17.3 (32/185) 8.6 (16/185) 0.5 (1/185) 1.6 (3/185) 4.3 (8/185) 25.9 (48/185)
Men 11.1 (29/261) 4.2 (11/261) 1.9 (5/261) 1.1 (3/261) 0.8 (2/261) 15.7 (41/261)
Summer events 13.5 (36/266) 4.9 (13/266) 2.3 (6/266) 0.4 (1/266) 1.5 (4/266) 18.0 (48/266)
Winter events 13.9 (25/180) 7.8 (14/180) 0 2.8 (5/180) 3.3 (6/180) 22.8 (41/180)
Speed and power athletes 11.5 (13/113) 5.3 (6/113) 2.7 (3/113) 0.9 (1/113) 1.8 (2/113) 16.8 (19/113)
Endurance athletes 24.1 (26/108) 9.3 (10/108) 1.9 (2/108) 2.8 (3/108) 3.7 (4/108) 33.3 (36/108)
Motor skill–demanding
events
8.2 (6/73) 2.7 (2/73) 1.4 (1/73) 0 1.4 (1/73) 12.3 (9/73)
Team sport athletes 10.5 (16/152) 5.9 (9/152) 0 1.3 (2/152) 2.0 (3/152) 16.4 (25/152)
Controls 11.0 (166/1503) 3.6 (54/1503) 3.1 (46/1503) 0.5 (7/1503) 1.8 (27/1503) 15.6 (235/1503)
Women 11.9 (88/738) 4.7 (35/738) 3.9 (29/738) 0.5 (4/738) 2.4 (22/738) 17.5 (129/738)
Men 10.2 (78/765) 2.5 (19/765) 2.2 (17/765) 0.4 (3/765) 0.7 (5/765) 13.9 (106/1503)
TABLE 2. Prevalence (%) of physician-diagnosed disturbing allergy, AR, allergic conjunctivitis, and atopic eczema in the study groups.
Disturbing
Allergy
Allergic
Rhinitis
Allergic
Conjunctivitis
Atopic
Eczema
All athletes 32.1 (143/446) 26.5 (118/446) 3.6 (16/446) 5.6 (25/446)
Women 30.8 (57/185) 26.5 (49/185) 4.9 (9/185) 7.0 (13/185)
Men 33.0 (86/261) 26.4 (69/261) 2.7 (7/261) 4.6 (12/261)
Summer events 32.7 (87/266) 27.4 (73/266) 3.0 (8/266) 4.9 (13/266)
Winter events 31.1 (56/180) 25.0 (45/180) 4.4 (8/180) 6.7 (12/180)
Speed and power athletes 27.4 (31/113) 20.4 (23/113) 1.8 (2/113) 2.7 (3/113)
Endurance athletes 43.5 (47/108) 36.1 (39/108) 4.6 (5/108) 9.3 (10/108)
Motor skill–demanding
events
35.6 (26/74) 27.4 (20/73) 4.1 (3/73) 9.6 (7/73)
Team sport athletes 25.7 (39/152) 23.7 (36/152) 3.9 (6/152) 3.3 (5/152)
Controls 30.1 (453/1503) 20.2 (303/1503) 5.6 (87/1503) 8.4 (126/1503)
Women 31.0 (229/738) 20.3 (150/738) 6.5 (48/738) 12.3 (91/738)
Men 29.3 (224/765) 20.0 (153/765) 5.1 (39/765) 4.6 (35/765)
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DISCUSSION
Untreated AR may severely weaken athletes’ maximal
exercise performance. In accordance with that fact and pre-
vious studies, the current study showed that physician-
diagnosed AR and the use of antiallergic medication are
significantly more prevalent in the elite endurance athletes
than among other athletes or the general population. How-
ever, the prevalence of allergic conditions other than AR did
not differ between various groups of athletes and the general
population. Nearly half of the athletes with an AR diagnosis
did not take antiallergic medication. Thus, undertreatment
may also be a problem for elite athletes.
Validity of the data. A structured questionnaire was
used to evaluate the prevalence of AR and the use of
antiallergic medication by elite athletes as compared with a
large control population representing Finnish people of the
same age. Response rate was excellent exceeding 90% for
the athletes and 80% for the control subjects. The sample-
size requirement was calculated using study power of 80%
and Type I  error of 0.05. This gave 249 study subjects in
both groups, which we managed to recruit.
In the present study, 20% of the control population reported
having a physician-diagnosed AR. This corresponds well with
a previous study in our country. According to Vartiainen et al.
(21), a lifetime history of hay fever was reported by 21.9% of
the random sample population of 25- to 54-yr-old subjects
living in North Karelia, Finland. The principal aim of this study
was to evaluate use of antiallergic medication in Finnish elite
athletes as compared with people at large. Use of skin-prick
testing for all athletes and controls would have increased ob-
tained information. However, this would have required nearly
2000 skin-prick tests in the present study, which obviously is
not possible. Previously, Helenius et al. (9,11) have shown that
the occurrence of atopic allergy according to skin-prick tests is
much higher than self-reported physician diagnosed AR. In
addition, clinical pollen allergy (positive skin test to pollen
allergens and symptoms of allergic rhinoconjunctivitis) coin-
cides extremely well with self-reported physician diagnosed
AR (9,11).
Most of the winter sport athletes represent Caucasian white
populations. In addition, the athletes practice and compete
mostly in the same locations all year round in order to be able
to do training on snow. The authors believe that the results
obtained here for winter sport athletes are well generalized to
all winter sport athletes. However, summer sport athletes rep-
resent a more culturally and ethnically diverse population.
Thus, the results of summer sport athletes obtained here should
be generalized with caution. It can be argued that these athletes
live in the health system that enhances the identification of AR
and subsequent treatment. However, both controls and athletes
live in a similar society. In addition, the prevalence of AR was
very similar between controls and athletes in other than endur-
ance events.
Comparison with earlier studies. Helbling et al. (7)
surveyed 2961 elite Swiss athletes (response rate 70%) partic-
ipating in 68 sports. A total of 16.8% of the athletes indicated
that they had AR, and of these 59% needed medication during
the pollen season. In the present study, 26.5% of the athletes
reported AR, with 55% having medication for it.
Helenius et al. (9) found that clinical pollen allergy (a
positive skin-prick test (SPT) and symptoms of seasonal
allergic rhinoconjunctivitis (ARC) affected one third of the
endurance athletes competing in summer events. Katelaris et
al. (13) determined the incidence of seasonal ARC in a large
sample of Australian elite athletes (N  977). Of these,
49.5% had symptoms of ARC, 23% a history of asthma, and
10% of eczema. A total of 56% had a positive SPT to at least
one allergen tested, and 34% to at least one seasonal aller-
gen. Of the athletes, 25% met the criteria for a diagnosis of
seasonal ARC (a positive SPT to at least one seasonal
allergen and the presence of at least two symptoms of ARC).
Maiolo et al. (17) studied asthma and atopy in 1060
Italian athletes who were trying out for a position on the
Italian Olympic Team for the Sydney 2000 Olympic Games.
Of the studied athletes, 18.3% reported symptoms of atopy.
No significant gender differences were observed. A total of
14.5% of the athletes reported being diagnosed for AR
(15.5% of the males and 12.3% of the females). Symptoms
of rhinitis were more frequent in the subgroup of endurance
athletes than in the other groups. These findings correspond
well with our results and can be explained by the athletes’
increased exposure to airborne allergens especially in en-
TABLE 4. Logistic regression model on physician-diagnosed disturbing allergy, AR, and antiallergic medication used during the previous 12 months after adjusting for age
and sex.
Characteristic
Disturbing Allergy Allergic Rhinitis Oral Antihistamines
Intranasal
Corticosteroids
Any Antiallergic
Medication
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age (yr)
Under 21 1 1 1 1 1
21–24 1.07 0.83–1.37 1.04 0.79–1.37 1.27 0.87–1.84 0.65 0.35–1.21 1.18 0.86–1.62
Over 24 1.17 0.91–1.49 1.07 0.81–1.41 1.33 0.92–1.92 1.49 0.88–2.52 1.33 0.98–1.81
Sex
Women 1 1 1 1 1
Men 0.96 0.79–1.17 0.99 0.80–1.23 0.78 0.59–1.04 0.50 0.32–0.79 0.69 0.54–0.88
Type of sports
None (controls) 1 1 1 1 1
Speed and power athletes 0.89 0.58–1.38 1.01 0.63–1.63 1.07 0.58–1.97 1.69 0.70–4.06 1.18 0.70–1.98
Endurance athletes 1.79 1.21–2.67 2.24 1.48–3.39 2.52 1.54–4.12 2.75 1.35–5.58 2.79 1.82–4.28
Motor skill–demanding events 1.33 0.81–2.19 1.51 0.89–2.56 0.76 0.32–1.79 0.77 0.18–3.22 0.81 0.40–1.66
Team sport athletes 0.82 0.56–1.21 1.25 0.84–1.89 0.92 0.57–1.71 1.60 0.77–3.34 1.11 0.70–1.74
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durance events (9). In contrast, the prevalence of allergic
conjunctivitis did not differ between athletes and controls in
the present study. This could be explained by the fact that
athletes’ conjunctivas do not receive such an increase of
airborne allergens as airway mucosal lining membrane does.
The upper respiratory tract functions as a physical filter, heat
exchanger, and humidifier for inhaled air. Thus, alteration of
upper airway function is expected to result in alteration of
lower airway function. According to Volcheck (22), AR should
be carefully assessed and aggressively controlled in order to
prevent the development of asthma or as integral part of asthma
treatment. Several epidemiologic studies have shown an asso-
ciation between AR and asthma (16). Guerra et al. (6) reported,
after controlling for age, sex, smoking status, and atopic status,
that rhinitis increased the risk of asthma threefold. In the
allergy report from the American Academy of Allergy,
Asthma, and Immunology, it was estimated that up to 38% of
patients with AR have asthma (2). In the present study, 34.7%
of the athletes with AR reported having asthma, whereas only
6.4% of the athletes not reporting AR had asthma.
Pharmacological management. No studies have eval-
uated in detail the use of antiallergic medication by elite ath-
letes. Treatment of AR could include avoiding allergens (usu-
ally not possible for athletes), taking intranasal corticosteroids,
short-term decongestants, oral or topical H1 receptor antago-
nists (antihistamines), intranasal cromoglycate, anticholinergic
agents, or by undergoing allergen immunotherapy (12).
Weiner et al. (23) conducted a meta-analysis of 16 evaluable
trials. Their analysis strongly indicates that intranasal cortico-
steroids are significantly more effective at relieving nasal
blockage, discharge, itch, and postnasal drip than are oral
antihistamines. Intranasal corticosteroids were also more effec-
tive at relieving sneezing and in reducing total nasal symptoms
than were the oral antihistamines, but there was significant
heterogeneity between the studies. Carrozzi et al. (5) reported
that preventive treatment with intranasal corticosteroids, sig-
nificantly improved symptoms of AR, quality of life, and
performance of Australian elite athletes. In the present study,
6% of the athletes and 3.6% of the control subjects reported
they had used intranasal corticosteroids.
In conclusion, endurance athletes have physician-diagnosed
AR, and they use antiallergic medication more often than
athletes in other events or control subjects. Female athletes use
antiallergic medication more frequently than male athletes.
Only half of those athletes reporting AR take antiallergic med-
ication. More attention thus needs to be paid to the optimal
management of AR in highly trained athletes.
The study was supported by Finnish National Olympic Commit-
tee, Finnish Ministry of Education, and Finnish Sports Research
Foundation.
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